Digest Network Come funziona
Network
/
Società
Nu
Non verificato

Numab Therapeutics AG

Di cosa scriviamo

Annunci EconomiciBiotecnologiaFinanzaManagement/Organizzazione AziendaleMedicina Salute Benessere

6 comunicati stampa

Guarda tutti i comunicati
18/12/2025
Biotecnologia
Medicina Salute Benessere
Annunci Economici
Numab Therapeutics Achieves Milestone in Second Collaboration Project with Boehringer Ingelheim
Fonte
Numab Therapeutics AG
Emittente
GLOBENEWSWIRE
1.00
0
13/11/2025
Biotecnologia
Numab Therapeutics and Kaken Pharmaceutical Announce Licensing and Co-development Agreement for Multispecific Antibody NM81 in Inflammatory Bowel Disease (IBD)
Fonte
Numab Therapeutics AG
Emittente
GLOBENEWSWIRE
1.00
0
25/09/2025
Biotecnologia
Medicina Salute Benessere
Management/Organizzazione Aziendale
Numab Therapeutics Achieves Milestone in Collaboration with Boehringer Ingelheim
Fonte
Numab Therapeutics AG
Emittente
GLOBENEWSWIRE
1.00
0
09/09/2025
Biotecnologia
Numab Therapeutics Announces Leadership Transition and Appoints Angehrn Pavik as Chief Executive Officer
Fonte
Numab Therapeutics AG
Emittente
GLOBENEWSWIRE
1.00
0
09/01/2025
Biotecnologia
Finanza
Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing
Fonte
Numab Therapeutics AG
Emittente
GLOBENEWSWIRE
1.00
0
30/10/2024
Biotecnologia
Medicina Salute Benessere
Numab Therapeutics Announces Initiation of Phase 1 Clinical Study of NM32 Program in Patients with Solid Tumors
Fonte
Numab Therapeutics AG
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0